| Literature DB >> 20971186 |
Giselle Pentón-Rol1, Gregorio Martínez-Sánchez, Majel Cervantes-Llanos, Nielsen Lagumersindez-Denis, Emilio Felino Acosta-Medina, Viviana Falcón-Cama, Ruby Alonso-Ramírez, Carmen Valenzuela-Silva, Efraín Rodríguez-Jiménez, Alexey Llópiz-Arzuaga, Javier Marín-Prida, Pedro Antonio López-Saura, Gerardo Emilio Guillén-Nieto, Eduardo Pentón-Arias.
Abstract
For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerosis (MS) animal model. C-Phycocyanin (C-Pc) has been reported to exhibit pharmacological properties that may be expected to symptomatically improve EAE and MS. However, in this paper we reveal a basic underlying mechanism that may provide a new approach to the rationale of the overall beneficial effect of this natural antioxidant. We demonstrate that C-Pc is able to trigger mechanisms preventing or downgrading EAE expression and induces a regulatory T cell (Treg) response, in peripheral blood mononuclear cells (PBMC) from MS patients. These results agree with reports suggesting that Treg limit acute MS attacks and that C-Pc may act as a neuroprotector and thereby reverts the organic and functional damage in neurodegenerative disorders of the central nervous system (CNS). Moreover, evidence is provided on the antioxidant activity of C-Pc within the CNS, intended to improve the myelin and axonal damage of EAE induced Lewis rats. Our results indicate that specific Treg activation may represent a central and essential mechanism in supporting the therapeutic potential of C-Pc for MS and may lead to new and more effective therapies; this property would then complement and enhance other proven active principles such as interferons (IFN), giving rise to combined therapies. Copyright ÂEntities:
Mesh:
Substances:
Year: 2010 PMID: 20971186 DOI: 10.1016/j.intimp.2010.10.001
Source DB: PubMed Journal: Int Immunopharmacol ISSN: 1567-5769 Impact factor: 4.932